

Histopathological Spectrum of Central Nervous System Tumours in Adolescent and Young Adults: A Cross-sectional Study from Punjab, Northern India

VIKRAM NARANG¹, GAGANDEEP SINGH², GURSHEEN PURI BATT³, ANKITA SONI⁴, HARPREET KAUR⁵

ABSTRACT

Introduction: Central Nervous System (CNS) tumours are a common cause of cancer-related deaths in adolescents and young adults. The challenges in diagnosing and treating CNS tumours in this age group are unique and require special attention.

Aim: To study the histopathological spectrum of CNS tumours in Adolescents and Young Adults (AYA).

Materials and Methods: Present five-year cross-sectional study was conducted on CNS biopsies received in the Department of Pathology at Dayanand Medical College and Hospital, Ludhiana, Punjab, India, from July 1, 2016, to June 30, 2021, to analyse the histopathological spectrum of CNS tumours in the AYA group based on the site of the lesion, age, gender, and Isocitrate Dehydrogenase (IDH) status.

Results: During the study period, a total of 215 cases of CNS tumours were identified, of which 52 (24.2%) belonged to the AYA group. Of these, 35 (67.3%) were males and 17 (32.7%) were females. The majority of the patients presented with complaints of headache (50/52, 96.1%), with the frontal lobe being the most common site of involvement (21/52, 40.4%). Diffuse astrocytic and oligodendroglial tumours were the most commonly observed (23/52, 44.2%).

Conclusion: CNS tumours are one of the most common cancer diagnosis among the AYA group, and awareness should be enhanced among histopathologists and oncologists regarding these tumours based on the updated classification.

INTRODUCTION

The AYA population has recently been recognised as an epidemiologically, biologically, and psychosocially unique group of patients [1]. CNS tumours are among the leading causes of cancer-related death in the 15- to 39-year-old age group [2]. The AYA patient population, aged between 15 and 39, faces multifactorial challenges in cancer care, attributed to unique tumour biologies in this group, limited research focus, and unmet psychosocial needs. Brain tumours encountered in AYAs generally have a slightly better prognosis than those encountered in older adults [3]. Therefore, AYAs with CNS tumours are likely to experience survivorship issues that adult neuro-oncologists may not always be experienced in handling [4]. Additionally, potential behavioural symptoms attributed to tumour location in the CNS or to medications such as steroids or antiepileptics may complicate an already emotionally tumultuous phase in the patient's life and may lead to misdiagnosis [4]. The literature focusing on AYAs with CNS malignancies is scarce in India; therefore, an attempt was made to study the histological spectrum of tumours in this epidemiologically, biologically, and psychosocially unique group [3-5].

MATERIALS AND METHODS

The present five-year cross-sectional study was conducted at the Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India, from July 2016 to June 2021. All intracranial space-occupying tumours were analysed with respect to the demographic profile, clinical, radiological, and histological data obtained from the institutional database. This included the age at presentation, gender, site of tumour, histological diagnosis, and WHO grade of tumour according to the WHO Classification of Tumours of the CNS 2016. Ethical clearance for the study

Keywords: Astrocytoma, Brain tumour, Glioblastoma, Intracranial space occupying lesion, Meningioma, Neoplasm

was obtained from the ethical committee via letter number BFUHS/2K21p-TH/5036.

Inclusion criteria: All CNS tumours in the age group 15-39 years were included in the study.

Exclusion criteria: Brain tumours in patients younger than 15 years and older than 39 years were excluded from the study.

According to this classification, the presence of certain mutations such as IDH in astrocytic tumours and co-deletion of 1p-19q in oligodendroglial tumours are considered the major deciding factors for grading and prognosis. Research shows that the presence of an IDH mutation is associated with a better prognosis, with evidence of increased overall and progression-free survival. This is because the IDH mutation increases the chemotherapeutic and radiotherapy sensitivity of gliomas [5].

AYA was defined according to various published literature as 15-39 years [1-3]. The histological spectrum was studied according to the WHO 2016 classification of tumours of the CNS [5]. The 2016 WHO Classification of Tumours of the CNS includes a grading system that assigns grades to various CNS tumours based on their histological features and aggressiveness. As per WHO 2016, further attempts were made to perform immunohistochemistry to subclassify the astrocytic tumours wherever possible. Further attempts were made in immunohistochemistry using IDH-1 to subclassify the astrocytomas as IDH wild-type and IDH mutant-type tumours wherever possible.

STATISTICAL ANALYSIS

The statistical analysis of the data involved using Statistical Package for Social Sciences (SPSS) Statistics 21.0 for Microsoft Windows (Chicago, USA). The data were described in terms of range,

mean±Standard Deviation (SD), frequencies (number of cases), and relative frequencies (percentage) as appropriate.

RESULTS

During the study period, a total of 215 cases of CNS tumours were identified, of which 52 (24.2%) belonged to the AYA group, where males (35) outnumbered females (17) (M:F=2:1). The majority of the patients presented with complaints of headache (50/52, 96.1%), while right/left-sided weakness (18/52, 34.6%) and seizure disorder (12/52, 23.07%) were the other common presentations. The frontal lobe was the most common site of involvement (40.4%), followed by the temporal lobe (21.2%) [Table/Fig-1]. Astrocytomas were the most common histopathological diagnosis (13/52, 25%), followed by oligodendroglial tumours (10/52, 19.2%), tumours of sellar origin (8/52, 15.3%), and meningiomas (7/52, 13.4%). Metastatic tumours and tumours of haematopoietic origin were the least common, with two cases each. The age group 15-19 years had fewer cases (n=8), whereas 20-30 years (n=22) and 30-39 years (n=22) did not show any variations [Table/Fig-2,3]. Of the 52 cases, immunohistochemistry was done only in four cases in this group, as the majority of the patients moved to a higher tertiary care centre

S. No.	Site of involvement	AYA (n=52)
1	Frontal lobe	21
2	Parietal lobe	5
3	Temporal lobe	11
4	Occipital lobe	1
5	Cerebellum	6
6	Sellar region	8

[Table/Fig-1]: Site wise distribution of CNS tumours in AYA group.

Classification	Histopathological subtypes	AYA (N=52)
Diffuse astrocytic and oligodendroglial tumours	Diffuse astrocytoma- IDH mutant	01
	Diffuse astrocytoma NOS	05
	Anaplastic astrocytoma IDH wild type	01
	Glioblastoma NOS	04
	Oligodendroglioma NOS	10
Other astrocytic tumours	Pilocytic astrocytoma	02
Ependymal tumours	Ependymoma	02
Embryonal tumours	Medulloblastoma histologically defined	02
	CNS neuroblastoma	01
Tumours of cranial and paraspinal nerves	Schwannoma	05
Meningiomas	Transitional	03
	Meningothelial	01
	Fibrous	01
	Atypical	01
	Anaplastic (malignant)	01
Lymphomas	Diffuse large B cell lymphoma of CNS	02
Tumours of sellar region	Craniopharyngioma	01
	Pituitary adenoma	07
Metastatic tumours	Metastatic carcinomatous deposits	02


[Table/Fig-2]: Spectrum of various CNS tumours in AYA group.

Histopathological subtypes		15-19 years (n=8)	20-30 years (n=22)	31-39 years (n=22)
Astrocytic tumours	Diffuse astrocytoma IDH mutant	00	00	01
	Diffuse astrocytoma NOS	00	04	01
	Anaplastic astrocytoma IDH wild type	00	00	01
	Glioblastoma NOS	00	01	03
	Pilocytic astrocytoma	01	01	00

Oligodendroglioma	00	05	05
Ependymoma	01	01	-
Meningioma	00	04	03
Embryonal tumours	01	01	01
Schwannoma	01	02	02
Others	04	03	05

[Table/Fig-3]: Age-wise prevalence of CNS tumours in AYA group.

for further evaluation and treatment. In astrocytic tumours, an attempt was made to further subclassify, with one case each of Diffuse astrocytoma IDH mutant, Anaplastic astrocytoma IDH wild type, and two cases of metastasis showing CK 7 positive and CK 20 negative, and CDX 2 positive, thus indicating a primary site of pancreatobiliary origin. Histopathological features of all these lesions have been demarcated in [Table/Fig-4].



[Table/Fig-4]: a) Diffuse astrocytoma- Tumour cells exhibits moderate nuclear pleomorphism, prominent nucleoli and moderate amount of cytoplasm (H&E 400X); b) Oligodendroglioma- Tumour cells are round having vesicular nuclei, perinuclear halo and moderate amount of cytoplasm (H&E 400X); c) Glioblastoma -Tumour showing geographic necrosis (arrow) palisaded by tumour cells (H&E 100X); d) Ependymoma- Perivascular pseudorosettes (arrow) formed by tumour cells arranged around blood vessels forming an anucleate zone (H&E 100X); e) Pilocytic astrocytoma- Tumour cells in sheets with presence of numerous Rosenthal fibres (long arrow) and eosinophilic granular bodies (short arrow) (H&E 400X); f) Meningothelial meningioma- Tumour cells are packed in fascicles, whorls, and syncytia having delicate chromatin and ill-defined cytoplasmic boundaries (H&E 400X); g) Desmoplastic medulloblastoma- Micrograph showing pale nodular areas surrounded by densely packed hyperchromatic cells (H&E 100X); h) Lymphoma -Expansion of blood vessel wall and dense infiltration by polymorphic cell population. (H&E 400X); i) Metastatic medulloblastoma- Micrograph showing pale nodular areas surrounded by densely packed hyperchromatic cells (H&E 100X); j) Metastatic carcinomatous deposits from lung- Tumour cells arranged in papillae, nests and focal glands (arrows) (H&E 100X).

DISCUSSION

AYAs have recently been recognised as an epidemiologically, biologically, and psychosocially distinct patient group. The majority

of published literature defines AYAs as patients aged 15 to 39 years. Patients in this age group develop rare CNS tumours or, in rare cases, common tumours. The current study found that low-grade astrocytomas and oligodendrogliomas were more common in the AYA group [6-8].

Over the last two decades, brain tumour research has clearly demonstrated that molecular assessment, rather than traditional histogenetic assessment using immunohistochemistry and electron microscopy, is more effective in characterising a tumour entity and evaluating the biological behaviour of brain tumours, particularly neuroepithelial tumours [5]. Many of the canonical genetic alterations had been identified by the time the WHO classification was published in 2007, but the majority view at the time was that such changes could not yet be used to define neoplasms. Instead, genetic status served as supplementary information within the framework of diagnostic categories established through standard histology-based means. Additionally, the 2016 classification added reliable molecular characteristics to the diffuse glioma classification [5]. The WHO CNS 5th edition recently restructured diffuse gliomas into adult-type and paediatric-type diffuse gliomas, with the latter further subdivided into low-grade and high-grade gliomas [9]. Despite paediatric-type diffuse gliomas sharing overlapping histology with adult-type gliomas, the biology and genetics are unique because they are generally indolent despite "anaplastic" histological features and lack IDH mutation and 1p/19q co-deletion, the genetic hallmarks of adult-type gliomas. However, they do have characteristic genetic profiling such as MAPK-pathway alteration [9]. This distinction is critical for distinguishing between these two prognostically and biologically distinct types of tumours, allowing for better care for both children and adults with CNS tumours. The age of the patient has no bearing on the definitions of paediatric-type and adult-type. Instead, they are classified based on common molecular changes, implying that paediatric-type gliomas can occur in adults and vice versa [10,11].

The spectrum and prevalence of CNS tumours in the AYA population differ by Indian region. Kakkar N et al., reported a similar histopathological spectrum in their study in North India, with astrocytoma being the most common (60/114), followed by oligodendrogliomas (21/114). In contrast to Kakkar N et al., present study found a higher prevalence of haematopoietic tumours and metastatic tumours, but no haemangiopericytoma or germinoma [12]. Singh R et al., reported a predominance of astrocytic tumours (11/22, 50%) in their study, but the prevalence of CNS tumours in AYA was 7.6% (22/287) [13]. In their study focusing on the AYA group, Kalyani R et al., found that the most common sites of malignancy in males were cancer of the mouth, stomach, testis, bone, and penis, and in females were cancer of the mouth, cervix uterus, breast, thyroid, and stomach [14]. AlMuhaisen GH et al., in their analysis of AYA CNS tumours, showed that gliomas comprised the most common histologic subtype (58.9%, n=218), followed by, in descending order, embryonal tumours (16.8%, n=62), ependymal tumours (7.8%, n=29), glioneuronal tumours (6.5%, n=24), and meningiomas (3.2%, n=12). The remaining 25% constituted a heterogeneous group composed of lymphomas, germ cell tumours, and vascular tumours, among others [15].

CNS tumours in AYAs are generally diagnosed late due to behavioural or psychiatric symptoms (frontal lobe syndrome). Other common symptoms include headaches, epileptic seizures, focal deficits, gait disturbances, and neurocognitive changes, in addition to behavioural changes [5,14]. Even after diagnosis, AYAs with CNS tumours present with unique endocrine and developmental issues, with therapeutic and survivor implications. Though data on the treatment of AYA patients with CNS tumours is limited at the institute, the standard protocol includes surgery as the mainstay

of treatment. For high-grade tumours, postsurgery radiotherapy with concurrent Temozolomide is used [16].

Furthermore, the lack of dedicated teams and units results in dispersed treatment and a scarcity of clinical trials specifically targeting the AYA group. Understanding the unique needs of people who have a brain tumour during a developmentally sensitive period and are likely to live long enough to experience its aftereffects is a critical component of managing brain tumours in AYAs [8,12,13]. AYAs are distinguished from older people with brain malignancies by these two features [15,17]. The patients are approached as either children or adults, which generates the biggest challenges with this age group [18-20]. Multidisciplinary teams treating AYAs with brain tumours should include adult and paediatric neuro-oncologists as well as endocrinologists [19,20]. AYAs find the Cushingoid phenotype especially distressing, but steroid use also causes osteopenia and Addisonian symptoms upon withdrawal [9,13,15]. Chemotherapy might cause infertility; as a result, preparations, including sperm banking and ovarian protection, are necessary [13,15].

Limitation(s)

The present study was limited by its small sample size and single-institute data.

CONCLUSION(S)

Brain tumours are common in AYAs, and the majority of these tumours are uncommon disease entities. Molecular profiling of all AYA brain tumours should be performed, not only for the purpose of diagnosis but also to explore the biology of the tumour. More research in a larger cohort, along with treatment and follow-up data, is warranted to assess the outcomes.

REFERENCES

- [1] Papageorgiou GI, Razis ED. CNS tumours in adolescents and young adults: The need for a holistic specialized approach. *JCO Oncol Pract* [Internet]. 2020;16(4):155-62.
- [2] Zapotocky M, Ramaswamy V, Lassaletta A, Bouffet E. Adolescents and young adults with brain tumours in the context of molecular advances in neuro-oncology. *Paediatr Blood Cancer*. 2018;65(2).
- [3] Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in adolescents and young adults: A narrative review of the current status and a view of the future. *JAMA Paediatr*. 2016;170(5):495-501.
- [4] Freyer DR, Seibel NL. The clinical trials gap for adolescents and young adults with cancer: Recent progress and conceptual framework for continued research. *Curr Paediatr Rep*. 2015;3(2):137-45.
- [5] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds): WHO Classification of Tumours of the Central Nervous System (Revised 4th edition). IARC; Lyon 2016.
- [6] Sender L, Zabokrtsky KB. Adolescent and young adult patients with cancer: A milieu of unique features. *Nat Rev Clin Oncol*. 2015;12(8):465-80.
- [7] Yeo KK, Burgers DE, Brodigan K, Fasciano K, Frazier AL, Warren KE, et al. Adolescent and young adult neuro-oncology: A comprehensive review. *Neurooncol Pract* [Internet]. 2021;8(3):236-46.
- [8] Katanoda K, Shibata A, Matsuda T, Hori M, Nakata K, Narita Y, et al. Childhood, adolescent and young adult cancer incidence in Japan in 2009-201. *Jpn J Clin Oncol*. 2017;47(8):762-71.
- [9] International Agency for Research on Cancer. WHO classification of tumours of the central nervous system: Who classification of tumours. 5th ed. Who Classification of Tumours Editorial Board, editor. IARC; 2022.
- [10] Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumours diagnosed in the United States in 2016-2020. *Neuro Oncol*. 2019;21(Suppl 5):v1-v100.
- [11] Close AG, Dreyzin A, Miller KD, Seynaeve BKN, Rapkin LB. Adolescent and young adult oncology-past, present, and future. *CA Cancer J Clin*. 2019;69(6):485-96.
- [12] Kakkar N, Gupta A, Sharma NK, Agarwal P, Kaur J. Adolescents and young adults: A study of distribution of cancer at ages 15-39 years in a tertiary care hospital from North India: Epidemiological considerations. *South Asian J Cancer*. 2017;06(04):180-82.
- [13] Singh R, Shirali R, Chatterjee S, Adhana A, Arora RS. Epidemiology of cancers among adolescents and young adults from a tertiary cancer center in Delhi. *Indian J Med Paediatr Oncol*. 2016;37(2):90-94.
- [14] Kalyani R, Das S, Kumar ML. Pattern of cancer in adolescent and young adults-A ten year study in India. *Asian Pac J Cancer Prev*. 2010;11(3):655-59.
- [15] AlMuhaisen GH, Al-Tarawneh B, Al-Hussaini M. Central nervous system tumours in adolescents and young adults: An epidemiological study from Jordan. *Neuroepidemiology*. 2020;54(4):326-33.

[16] Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. *Cochrane Database Syst Rev*. 2013;2013(4):CD007415.

[17] Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, et al. American Brain Tumour Association adolescent and young adult primary brain and central nervous system tumours diagnosed in the United States in 2008-2012. *Neuro-oncol*. 2016;18:i1-i50.

[18] Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Birch JM, et al. Age-incidence patterns of primary CNS tumours in children, adolescents, and adults in England. *Neuro-Oncol*. 2009;11(4):403-13.

[19] Leibetseder A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K, et al. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: A study of the Society of Austrian Neurooncology (SANO). *Neuro-oncol*. 2013;15(1):112-21.

[20] Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, et al. Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. *Eur J Cancer*. 2017;86:46-58.

PARTICULARS OF CONTRIBUTORS:

1. Professor, Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
2. Senior Resident, Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
3. Consultant, Department of Medicine, Oswal Cancer Hospital, Ludhiana, Punjab, India.
4. Assistant Professor, Department of Pathology, AIIMS, Bathinda, Punjab, India.
5. Professor and Head, Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Vikram Narang,
Professor, Department of Pathology, Dayanand Medical College and Hospital,
Tagore Nagar, Ludhiana-141001, Punjab, India.
E-mail: drvikramnarang@yahoo.com

PLAGIARISM CHECKING METHODS: [\[Jain H et al.\]](#)

- Plagiarism X-checker: Jul 08, 2023
- Manual Googling: Nov 03, 2023
- iThenticate Software: Nov 05, 2023 (11%)

ETYMOLOGY: Author Origin

EMENDATIONS: 8

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? No
- For any images presented appropriate consent has been obtained from the subjects. No

Date of Submission: Jul 03, 2023

Date of Peer Review: Sep 18, 2023

Date of Acceptance: Nov 07, 2023

Date of Publishing: Feb 01, 2024